Milestones Week 4 96.9 kg -3.1% from baseline Week 12 91.7 kg -8.3% from baseline Week 24 85.5 kg -14.5% from baseline Week 36 82.1 kg -17.9% from baseline Week 48 80.1 kg -19.9% from baseline Week 60 79.1 kg -20.9% from baseline Week 72 78.4 kg -21.6% from baseline What this tool helps you do This calculator estimates a trial-average timeline to a goal weight using embedded weekly weight-loss curves for tirzepatide, semaglutide, and retatrutide
Unfortunately, most biologics are still in clinical trials, although further efforts are underway to develop safe and durable treatment strategies
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes
Although our study identified GLP-1R as a key therapeutic target in lung fibroblasts during silica-induced pulmonary fibrosis, the antifibrotic effect of GLP-1R activation may not be solely attributable to targeting fibroblasts for the prevention of silica-induced pulmonary fibrosis
Tirzepatide is a once-weekly injectable medication approved by the FDA for the treatment of type 2 diabetes (marketed as Mounjaro) and chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity (marketed as Zepbound)
